Carmustine (BCNU)

Carmustine is an antineoplastic agent and member of the nitrosourea family of alkylating agents, used primarily as chemotherapy for brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphoma. Carmustine acts by forming DNA crosslinks and inhibiting DNA and RNA synthesis, leading to cell death[6][4]. It is not a biological target (such as a receptor, enzyme, or transporter), but a small molecule drug that acts directly upon such targets. The canonical abbreviation is BCNU, and it is also known by several trade names including BiCNU and Gliadel[1][3][7]. - Carmustine is not a therapeutic target (receptor, enzyme, etc.)—it is the name of a drug and not a molecule or protein in the body that could act as a drug target[6][4]. - The entry is therefore classified as is_incorrect: true for the requested context. - All aliases and chemical detail are provided for future mapping or cross-referencing. - No molecular class, biological function, or disease role is applicable to carmustine as a target—it is a drug, not a target[7][2][6].

Other names

BCNUBiCNU1,3-bis(2-chloroethyl)-1-nitrosoureaCarmustinGliadelBecenunDTI 015FDA 0345NitrumonSK 27702SRI 1720